Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer

Next Previous
Trial Profile

Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Sep 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exemestane (Primary)
  • Indications Advanced breast cancer; Early breast cancer
  • Focus Adverse reactions
  • Sponsors Pfizer

Most Recent Events

  • 11 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
  • 03 Jan 2013 Planned end date changed from 1 Aug 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov.
  • 28 Nov 2011 Planned end date changed from 1 Apr 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top